ONVO is written about today concerning it's future listing prospects with Nasdaq,
Organovo also stands alone in a niche market as it is the only company in its industry developing a three-dimensional printing apparatus for the printing of human tissues, known as the NovoGen MMX Bioprinter that was developed to meet challenges in biologic research. The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology which can be viewed as a superior analysis alternative to animal testing models (for a more in depth analysis please see company website). The MMX Bioprinter has already demonstrated the ability to create human blood vessel constructs, effectively creating human tissue capillary structures. This showcases the company's potential to broaden the scope and scale of 3D tissues that can be generated, and facilitates the development of disease models in such areas as cardiovascular disease, fibrosis and oncology. In addition to being the only player in the market segment, Organovo has successfully secured collaborations and research agreements with Pfizer (PFE), United Therapeutics (UTHR) and Autodesk (ADSK) from which they derive revenue and valuable insight and analysis into developing their technology.
As I previously stated, uplisiting to a national exchange like the NYSE-MKT or NASDAQ-CM generates advantages in broader visibility, increased liquidity and accessibility to the deep pockets of institutional investment firms and retail brokers.
Of particular importance, participation will widen as the listing will open trading to a sizeable proportion of investors who are unable to, or avoid over-the-counter investment(s). As both these companies inch towards the final steps of completing the process to uplist, retail investors seeking exposure to the niche markets that only InVivo and Organovo offer still have a chance to invest before the monetary benefits of the uplisting come to full fruition when institutional money and greater visibility will factor into the price.
